ARVN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

37.26M

-37.06%

-0.555

-11.84%

21.89M

-88.41%

-0.784

-168.76%

22.06M

-1.5%

-0.807

-3.87%

Estimates Revision

The market is revising Upward the revenue expectations for Arvinas, Inc. (ARVN) for FY2025, with the revenue forecasts being adjusted by 2.38% over the past three months. During the same period, the stock price has changed by 60.08%.

Revenue Estimates for FY2025

Revise Upward

+2.38%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.12%

In Past 3 Month

Stock Price

Go Up

+60.08%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 20.62 USD with a low forecast of 6.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

6 Hold

1 Sell

Moderate Buy

Current: 12.390

Low

6.00

Averages

20.62

High

110.00

Current: 12.390

Low

6.00

Averages

20.62

High

110.00

BTIG

NULL -> Buy

initiated

$45

2025-12-10

New

Reason

BTIG

Price Target

$45

2025-12-10

New

initiated

NULL -> Buy

Reason

BTIG initiated coverage of ArriVent Biopharma with a Buy rating and $45 price target.

Stephens

Loganathan

Overweight

maintain

$14 -> $15

2025-11-10

Reason

Stephens

Loganathan

Price Target

$14 -> $15

2025-11-10

maintain

Overweight

Reason

Stephens analyst Sudan Loganathan raised the firm's price target on Arvinas to $15 from $14 and keeps an Overweight rating on the shares. Q3 results were broadly in-line, notes the analyst, who sees forward value in ARV-393, ARV-102, and ARV-806 given "encouraging" early data across these assets and now incorporates ARV-102 into the firm's valuation framework.

BTIG

Buy

upgrade

$10 -> $14

2025-10-30

Reason

BTIG

Price Target

$10 -> $14

2025-10-30

upgrade

Buy

Reason

BTIG raised the firm's price target on Arvinas to $14 from $10 and keeps a Buy rating on the shares. Shares have sold off following the vepdeg reset, but the combination of current valuation, potential of KRASG12D as a target in large indications such as NSCLC and PDAC, and ability for ARV-806 to clinically differentiate all have the firm leaning into the stock ahead of the data, the analyst tells investors in a research note, adding that the firm is also including ARV-806 in its model.

Goldman Sachs

Neutral -> Sell

downgrade

$8 -> $6

2025-10-15

Reason

Goldman Sachs

Price Target

$8 -> $6

2025-10-15

downgrade

Neutral -> Sell

Reason

Goldman Sachs downgraded Arvinas to Sell from Neutral with a price target of $6, down from $8. The firm says the "rapidly evolving" competitive landscape for hormone receptor-positive/HER2-negative metastatic breast cancer puts the company's vepdegestrant at increasing risk of obsolescence. Arvinas competitors' progress has taken some of the interest away from vepdegestrant and has made an out-licensing deal more challenging, the analyst tells investors in a research note. Goldman thinks the shares will largely trade on cash burn considerations.

Stephens

Sudan Loganathan

Overweight

downgrade

$16 -> $14

2025-09-18

Reason

Stephens

Sudan Loganathan

Price Target

$16 -> $14

2025-09-18

downgrade

Overweight

Reason

Stephens analyst Sudan Loganathan lowered the firm's price target on Arvinas (ARVN) to $14 from $16 and keeps an Overweight rating on the shares after the company announced an update on its collaboration with Pfizer (PFE) for the co-development of vepdegestrant. The companies will out-license commercialization rights to a third party and have begun the partner search process and Arvinas will refocus its operations by reducing vepdeg related expenses, cutting about 15% of its workforce and reallocating capital to ARV-102, ARV-393, and ARV-806, notes the analyst, who calls this "an unsurprising outcome." Given the increased uncertainty surrounding vepdeg's commercial outlook, the firm reduced its estimate of Arvinas' attributed peak sales for vepdeg in 2035 to $641.2M from $966.2M previously forecast.

BTIG

Buy

downgrade

$16 -> $10

2025-09-18

Reason

BTIG

Price Target

$16 -> $10

2025-09-18

downgrade

Buy

Reason

BTIG lowered the firm's price target on Arvinas (ARVN) to $10 from $16 and keeps a Buy rating on the shares. The company provided an update on its collaboration agreement with Pfizer (PFE) for vepdegestrant, noting the two will jointly select a third party for outl-icensing and commercialization, the analyst tells investors in a research note. The firm says Arvinas management is optimistic on finding a new partner before the June 2026 FDA action note, but highlights the "very tight timeline." BTIG views the news as a "reset" for Arvinas which provides an opportunity to focus on its internal programs for oncology and neuroscience. It sees an attractive entry point for the shares.

Valuation Metrics

The current forward P/E ratio for Arvinas Inc (ARVN.O) is -4.22, compared to its 5-year average forward P/E of 77.92. For a more detailed relative valuation and DCF analysis to assess Arvinas Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

77.92

Current PE

-4.22

Overvalued PE

459.11

Undervalued PE

-303.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.87

Current EV/EBITDA

-0.14

Overvalued EV/EBITDA

33.78

Undervalued EV/EBITDA

-61.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.06

Current PS

7.64

Overvalued PS

48.97

Undervalued PS

-2.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARVN News & Events

Events Timeline

No data

News

9.0

12-06Globenewswire

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026

9.0

12-06Newsfilter

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL, Expected in 2026

1.0

11-26Globenewswire

Arvinas to Participate in Piper Sandler Healthcare Conference on December 4

People Also Watch

Frequently Asked Questions

What is Arvinas Inc (ARVN) stock price today?

The current price of ARVN is 12.39 USD — it has decreased -1.51 % in the last trading day.

What is Arvinas Inc (ARVN)'s business?

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

What is the price predicton of ARVN Stock?

What is Arvinas Inc (ARVN)'s revenue for the last quarter?

Arvinas Inc revenue for the last quarter amounts to 41.90M USD, decreased -59.08 % YoY.

What is Arvinas Inc (ARVN)'s earnings per share (EPS) for the last quarter?

Arvinas Inc. EPS for the last quarter amounts to -0.48 USD, decreased -29.41 % YoY.

What changes have occurred in the market's expectations for Arvinas Inc (ARVN)'s fundamentals?

How many employees does Arvinas Inc (ARVN). have?

Arvinas Inc (ARVN) has 430 emplpoyees as of December 15 2025.

What is Arvinas Inc (ARVN) market cap?

Today ARVN has the market capitalization of 807.94M USD.